scholarly journals L-type amino acid transporter 1 (LAT1)-specific inhibitor is effective against T cell-mediated nasal hyperresponsiveness

2020 ◽  
Vol 69 (3) ◽  
pp. 455-458
Author(s):  
Osamu Kaminuma ◽  
Tomoe Nishimura ◽  
Mayumi Saeki ◽  
Norimasa Yamasaki ◽  
Sawako Ogata ◽  
...  
2001 ◽  
Vol 358 (3) ◽  
pp. 693-704 ◽  
Author(s):  
Tomoko NII ◽  
Hiroko SEGAWA ◽  
Yutaka TAKETANI ◽  
Yoshiko TANI ◽  
Makiko OHKIDO ◽  
...  

We investigated the regulation of system-L amino acid transporter (LAT1) during T-cell activation. In quiescent T-cells, l-leucine transport is mediated mainly by the system-L amino acid transport system and is increased significantly during T-cell activation by PMA and ionomycin. In quiescent T-cells, the LAT1 protein was heterocomplexed with 4F2 heavy chain (4F2hc) in the plasma membrane. During T-cell activation, the amounts of 4F2hc and LAT1 heterocomplex were significantly elevated compared with those in quiescent T-cells. In addition, by Northern-blot analysis, these increments were found to be due to elevated levels of LAT1 and 4F2hc mRNA. Transient expression of constructs comprising various LAT1 gene promoter fragments, which contained all three of the GC boxes, was sufficient for promoting luciferase expression in Jurkat T-cells, but the promoter of the LAT1 gene did not respond to PMA and ionomycin. Similar observations were observed in the human 4F2hc gene promoter. In nuclear run-on assay, the LAT1 and 4F2hc genes were actively transcribed even in quiescent T-cells, but the low levels of both transcripts were shown to be the result of a block to transcription elongation within the exon 1 intron 1 regions. These findings indicated that a removal of the block to mRNA elongation stimulates the induction of system-L amino acid transporter gene transcripts (LAT1 and 4F2hc) in activated T-cells.


Immunity ◽  
2014 ◽  
Vol 40 (5) ◽  
pp. 692-705 ◽  
Author(s):  
Mako Nakaya ◽  
Yichuan Xiao ◽  
Xiaofei Zhou ◽  
Jae-Hoon Chang ◽  
Mikyoung Chang ◽  
...  

2015 ◽  
Vol 46 (1) ◽  
pp. 92-103 ◽  
Author(s):  
Anke Werner ◽  
Eva Amann ◽  
Vanessa Schnitzius ◽  
Alice Habermeier ◽  
Claudia Luckner-Minden ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Narangerel Jigjidkhorloo ◽  
Kohsuke Kanekura ◽  
Jun Matsubayashi ◽  
Daigo Akahane ◽  
Koji Fujita ◽  
...  

AbstractL-type neutral amino acid transporter 1 (LAT1) is a heterodimeric membrane transport protein involved in neutral amino acid transport. LAT1 is highly expressed in various malignant solid tumors and plays an essential role in cell proliferation. However, its role in malignant lymphoma remains unknown. Here, we evaluated LAT1 expression level in tissues from 138 patients with Non-Hodgkin lymphoma (NHL). Overexpression of LAT1 was confirmed in all types of NHL and we found that there is a significant correlation between the level of LAT1 expression and lymphoma grade. The LAT1 expression was higher in aggressive types of lymphomas when compared with static types of lymphomas, suggesting that active tumor proliferation requires nutrient uptake via LAT1. The expression level of LAT1 was inversely correlated with patients’ survival span. Furthermore, pharmacological inhibition of LAT1 by a specific inhibitor JPH203 inhibits lymphoma cell growth. In conclusion, our study demonstrated that LAT1 expression can be used as a prognostic marker for patients with NHL and targeting LAT1 by JPH203 can be a novel therapeutic modality for NHL.


Sign in / Sign up

Export Citation Format

Share Document